샘플 요청 목록

 카트 문의
시장보고서
상품코드
1542758

세계의 C 반응성 단백질 검사 시장

C-Reactive Protein Testing
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 244 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

C 반응성 단백질 검사 세계 시장은 2030년까지 32억 달러에 달할 것으로 예상됩니다

2023년 29억 달러로 추정되는 C 반응성 단백질 검사 세계 시장은 2023년부터 2030년까지 연평균 복합 성장률(CAGR) 1.8%로 성장하여 2030년에는 32억 달러에 이를 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 심혈관 질환의 C 반응성 단백질 검사는 CAGR 2.6%를 기록하여 분석 기간 종료 시점에 9억 5,530만 달러에 도달할 것으로 예측됩니다. 암 질환 분야의 C 반응성 단백질 검사의 성장률은 분석 기간 동안 CAGR 2.1%로 추정됩니다.

미국 시장 8억 4,410만 달러로 추정, 중국은 CAGR 1.7%로 성장 전망

미국의 C 반응성 단백질 검사 시장은 2023년 8억 4,410만 달러에 달할 것으로 추정됩니다. 세계 2위의 경제 대국인 중국은 2023년부터 2030년까지 연평균 1.7%의 성장률을 보이며 2030년에는 5억 8,100만 달러 규모에 이를 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 1.7%와 1.3%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 연평균 1.9%의 성장률을 보일 것으로 예상됩니다.

세계 C-반응성 단백질 검사 시장 - 주요 동향 및 촉진요인 요약

염증을 넘어 C 반응성 단백질 검사는 미국에 무엇을 가져올 것인가?

C 반응성 단백질(CRP) 검사는 염증에 반응하여 간에서 생성되는 단백질인 혈중 CRP 수치를 측정하기 위해 고안된 널리 사용되는 진단 도구로, CRP의 존재는 급성 감염에서 만성 질환, 자가면역 질환에 이르기까지 다양한 질병과 관련이 있습니다. 수치를 측정함으로써 의료진은 체내 염증 여부를 평가하고, 그 심각성을 판단하고, 치료 효과를 모니터링할 수 있습니다. 이 검사는 일반적으로 CRP 상승을 유발하는 세균 감염과 바이러스 감염을 구별하고 류마티스 관절염이나 크론병과 같은 만성 염증성 질환의 치료 지침이 될 수 있기 때문에 특히 가치가 높습니다.

기술이 CRP 검사의 정확성과 접근성을 어떻게 향상시키고 있는가?

의료기술의 발전으로 CRP 검사의 정확성과 유용성이 크게 향상되었습니다. 최신 CRP 검사는 몇 분 안에 결과를 얻을 수 있어 신속한 임상적 판단을 가능하게 합니다. 특히 환자의 침대 옆이나 진료실에서 직접 사용할 수 있는 현장 진료용 CRP 검사 장비는 특히 획기적입니다. 검사실로 샘플을 보낼 필요가 없고, 결과를 기다리는 시간도 단축할 수 있습니다. 또한, 최근 마이크로플루이딕스공학 및 바이오센싱 기술의 발전은 적은 양의 혈액 샘플을 필요로 하는 더 작고 민감한 CRP 검사 장비의 개발로 이어지고 있습니다.

CRP 검사 실시에 어떤 문제가 있는가?

CRP 검사의 장점에도 불구하고, CRP 검사 시행에는 몇 가지 문제가 있습니다. 주요 우려 사항 중 하나는 CRP 값이 확정적인 진단 정보를 제공하지 않는 상황에서 CRP 검사가 과도하게 사용되거나 오용될 수 있으며, CRP 결과를 잘못 해석하면 바이러스 감염에 대한 부적절한 항생제 사용과 같은 불필요한 치료로 이어질 수 있다는 점입니다. 수 있습니다. 또한, 현장 진료 CRP 검사는 편리함을 제공하지만, 모든 의료 현장에서 CRP 검사의 정확성과 신뢰성을 보장하는 것이 중요하지만, CRP 검사의 장점을 극대화하고 잠재적인 단점을 피하기 위해서는 CRP 검사 결과를 이해하고 임상 현장에 효과적으로 통합할 수 있는 의료진들의 인식이 필요합니다. 임상 현장에서 CRP 검사 결과를 이해하고 효과적으로 통합할 수 있도록 의료진을 교육하는 것이 필수적입니다.

CRP 검사 시장 확대에 박차를 가하는 주요 요인은?

C 반응성 단백질 검사 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 심혈관 질환, 류마티스 관절염, 염증성 장 질환과 같은 염증성 질환의 유병률이 증가함에 따라 CRP 검사와 같은 효과적인 진단 및 모니터링 도구에 대한 수요가 증가하고 있습니다. 염증의 중요성과 다양한 건강 상태에서의 염증의 역할에 대한 의사와 환자의 인식이 높아진 것도 이러한 추세에 기여하고 있습니다. 또한, 현장 진단의 확대와 저렴한 가격의 신속한 CRP 검사 장비의 보급이 확대됨에 따라 보다 많은 사람들이 CRP 검사를 쉽게 이용할 수 있게 되었습니다. 의료 시스템이 예방과 조기 개입을 중시하는 가운데, CRP 검사는 의료의 소중한 무기로 자리매김하며 다양한 의료 환경에서 채택과 시장 성장을 가속하고 있습니다.

조사 대상 기업 예시(주목받는 43개 기업)

  • Abaxis, Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Laboratory Corporation of America Holdings(LabCorp)
  • Merck KgaA
  • Quest Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

    목차

    제1장 조사 방법

    제2장 주요 요약

    • 시장 개요
    • 주요 기업
    • 시장 동향과 촉진요인
    • 세계 시장 전망

    제3장 시장 분석

    • 미국
    • 캐나다
    • 일본
    • 중국
    • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 기타 유럽
    • 아시아태평양
    • 기타 지역

    제4장 경쟁

    LSH 24.09.03

    Global C-Reactive Protein Testing Market to Reach US$3.2 Billion by 2030

    The global market for C-Reactive Protein Testing estimated at US$2.9 Billion in the year 2023, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2023-2030. C-Reactive Protein Testing for Cardiovascular Diseases, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$955.3 Million by the end of the analysis period. Growth in the C-Reactive Protein Testing for Cancer Disease segment is estimated at 2.1% CAGR over the analysis period.

    The U.S. Market is Estimated at US$844.1 Million While China is Forecast to Grow at 1.7% CAGR

    The C-Reactive Protein Testing market in the U.S. is estimated at US$844.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$581.0 Million by the year 2030 trailing a CAGR of 1.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

    Global C-Reactive Protein Testing Market - Key Trends and Drivers Summarized

    Beyond Inflammation: What Can C-Reactive Protein Testing Really Tell Us?

    C-reactive protein (CRP) testing is a widely used diagnostic tool designed to measure the level of CRP in the blood, a protein produced by the liver in response to inflammation. The presence of CRP is associated with a variety of conditions, from acute infections to chronic diseases and autoimmune disorders. By measuring CRP levels, healthcare providers can assess if there is an inflammation in the body, determine its severity, and monitor the effectiveness of treatment. This test is particularly valuable because it can help distinguish between bacterial infections, which typically cause a higher CRP elevation, and viral infections, alongside guiding therapy in chronic inflammatory conditions like rheumatoid arthritis and Crohn's disease.

    How Is Technology Enhancing CRP Testing Accuracy and Accessibility?

    The accuracy and utility of CRP testing have significantly improved with advancements in medical technology. Modern CRP tests can deliver results in a matter of minutes, allowing for rapid clinical decision-making. Point-of-care CRP testing devices, which can be used directly at the patient’s bedside or in the doctor's office, are particularly revolutionary. They eliminate the need to send samples to a lab and reduce the waiting time for results. Moreover, recent developments in microfluidics and biosensing technologies have led to the creation of even smaller, more sensitive CRP testing devices that require only a tiny blood sample, making the test less invasive and more comfortable for patients.

    What Challenges Are Faced in the Implementation of CRP Testing?

    Despite its benefits, the implementation of CRP testing faces certain challenges. One of the primary concerns is the potential for overuse or misuse of the test, particularly in situations where CRP levels may not provide definitive diagnostic information. Misinterpretation of CRP results can lead to unnecessary treatments, such as the inappropriate use of antibiotics for viral infections. Additionally, while point-of-care CRP testing offers convenience, ensuring the accuracy and reliability of these devices across all healthcare settings is critical but challenging. Training healthcare providers to understand and integrate CRP test results effectively into the clinical context is also essential to maximize the test's benefits and avoid potential drawbacks.

    What Key Factors Are Fueling the Expansion of the CRP Testing Market?

    The growth in the C-Reactive Protein testing market is driven by several factors. The rising prevalence of inflammatory diseases such as cardiovascular disorders, rheumatoid arthritis, and inflammatory bowel disease has led to an increased demand for effective diagnostic and monitoring tools like CRP testing. Growing awareness among physicians and patients about the importance of inflammation and its role in various health conditions also contributes to this trend. Additionally, the expansion of point-of-care diagnostics and the increasing availability of affordable and rapid CRP testing devices have made these tests more accessible to a broader segment of the population. As health systems continue to emphasize preventive care and early intervention, CRP testing is positioned as a valuable tool in the medical arsenal, promoting its adoption and market growth across diverse healthcare environments.

    Select Competitors (Total 43 Featured) -

    • Abaxis, Inc.
    • Abbott Laboratories
    • Danaher Corporation
    • F. Hoffmann-La Roche AG
    • Laboratory Corporation of America Holdings (LabCorp)
    • Merck KgaA
    • Quest Diagnostics, Inc.
    • Randox Laboratories Ltd.
    • Siemens Healthineers
    • Thermo Fisher Scientific, Inc.

    TABLE OF CONTENTS

    I. METHODOLOGY

    II. EXECUTIVE SUMMARY

    • 1. MARKET OVERVIEW
      • Influencer Market Insights
      • C-Reactive Protein Testing - Global Key Competitors Percentage Market Share in 2024 (E)
      • Impact of COVID-19 Pandemic and Looming Global Recession
      • What is C-reactive Protein (CRP)?
      • An Introduction to C-reactive Protein Testing
      • Global Market Prospects & Outlook
      • Immunoturbidimetric Assays: The Major Segment by Assay Type
      • hs-CRP Test Type Leads by Detection Range
      • Cardiovascular Diseases Emerge As the Leading Disease Type for CRP Testing, Cancer Detection to Make Strong Gains
      • Clinics & Hospitals Hold Dominant Share of CRP Testing Market
      • Developed Regions Lead, Developing Economies to Spur Market Growth
      • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • 2. FOCUS ON SELECT PLAYERS
    • 3. MARKET TRENDS & DRIVERS
      • Rising Prominence of POC Testing Approaches for C-reactive Protein Testing Enable Faster and Accurate Results
      • CRP Testing for Ascertaining Viral Infections
      • Growing Incidence of HIV Infections and Need for Monitoring of HIV Diseases Drive CRP Testing
      • Threat of Endometriosis in Women: Significant Role of CRP Testing
      • CRP Testing: A Vital Diagnostic Tool for Cancer
      • CRP Testing Holds Potential Role in Assessing Effectiveness of Antibiotic Drugs
      • Funding Support for Extensive Research on Applications of C-reactive Protein Testing to Boost Market Growth
      • Growing Use of CRP Testing in Cardiovascular Risk Assessment Bolsters Market Growth
      • Integration of CRP Testing in Routine Check-ups Enhances Early Detection Rates
      • Research Linking Inflammation to Various Chronic Diseases Strengthens Test Demand
      • Emerging Markets Offer Significant Opportunities Due to Expanding Healthcare Systems
    • 4. GLOBAL MARKET PERSPECTIVE
      • TABLE 1: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 2: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 3: World 16-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 4: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 5: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 6: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 7: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 8: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 9: World 16-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 10: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 11: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 12: World 16-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 13: World Recent Past, Current & Future Analysis for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 14: World Historic Review for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 15: World 16-Year Perspective for Endometriosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 16: World Recent Past, Current & Future Analysis for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 17: World Historic Review for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 18: World 16-Year Perspective for Lupus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 19: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 20: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 21: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 22: World Recent Past, Current & Future Analysis for Immunoturbidimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 23: World Historic Review for Immunoturbidimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 24: World 16-Year Perspective for Immunoturbidimetric Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 25: World Recent Past, Current & Future Analysis for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 26: World Historic Review for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 27: World 16-Year Perspective for ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 28: World Recent Past, Current & Future Analysis for Chemiluminescence Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 29: World Historic Review for Chemiluminescence Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 30: World 16-Year Perspective for Chemiluminescence Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 31: World Recent Past, Current & Future Analysis for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 32: World Historic Review for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 33: World 16-Year Perspective for Other Assay Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 34: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 35: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 36: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 37: World Recent Past, Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 38: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 39: World 16-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 40: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 41: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 42: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 43: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 44: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 45: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
      • TABLE 46: World C-Reactive Protein Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
      • TABLE 47: World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 48: World Historic Review for C-Reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 49: World 16-Year Perspective for C-Reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030

    III. MARKET ANALYSIS

    • UNITED STATES
      • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
      • TABLE 50: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 51: USA Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 52: USA 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 53: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 54: USA Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 55: USA 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 56: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 57: USA Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 58: USA 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • CANADA
      • TABLE 59: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 60: Canada Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 61: Canada 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 62: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 63: Canada Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 64: Canada 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 65: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 66: Canada Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 67: Canada 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • JAPAN
      • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
      • TABLE 68: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 69: Japan Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 70: Japan 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 71: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 72: Japan Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 73: Japan 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 74: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 75: Japan Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 76: Japan 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • CHINA
      • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
      • TABLE 77: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 78: China Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 79: China 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 80: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 81: China Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 82: China 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 83: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 84: China Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 85: China 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • EUROPE
      • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
      • TABLE 86: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 87: Europe Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 88: Europe 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 89: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 90: Europe Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 91: Europe 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 92: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 93: Europe Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 94: Europe 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
      • TABLE 95: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 96: Europe Historic Review for C-Reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 97: Europe 16-Year Perspective for C-Reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • FRANCE
      • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
      • TABLE 98: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 99: France Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 100: France 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 101: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 102: France Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 103: France 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 104: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 105: France Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 106: France 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • GERMANY
      • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
      • TABLE 107: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 108: Germany Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 109: Germany 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 110: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 111: Germany Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 112: Germany 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 113: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 114: Germany Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 115: Germany 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • ITALY
      • TABLE 116: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 117: Italy Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 118: Italy 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 119: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 120: Italy Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 121: Italy 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 122: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 123: Italy Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 124: Italy 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • UNITED KINGDOM
      • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
      • TABLE 125: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 126: UK Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 127: UK 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 128: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 129: UK Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 130: UK 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 131: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 132: UK Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 133: UK 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • REST OF EUROPE
      • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 135: Rest of Europe Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 136: Rest of Europe 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 138: Rest of Europe Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 139: Rest of Europe 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 141: Rest of Europe Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 142: Rest of Europe 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • ASIA-PACIFIC
      • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
      • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 144: Asia-Pacific Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 145: Asia-Pacific 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 147: Asia-Pacific Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 148: Asia-Pacific 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 150: Asia-Pacific Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 151: Asia-Pacific 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • REST OF WORLD
      • TABLE 152: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 153: Rest of World Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 154: Rest of World 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
      • TABLE 155: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 156: Rest of World Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 157: Rest of World 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
      • TABLE 158: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 159: Rest of World Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 160: Rest of World 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030

    IV. COMPETITION

    • 샘플 요청 목록
    0 건의 상품을 선택 중
    목록 보기
    전체삭제